entinostat and Recrudescence
entinostat has been researched along with Recrudescence in 3 studies
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from antibody-drug conjugates targeting CD30 and immune checkpoint antibodies." | 2.82 | ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. ( Batlevi, CL; Bociek, RG; Buglio, D; Copeland, A; Cruickshank, S; Gore, L; Hernandez-Ilizaliturri, F; Kasamon, Y; Kunkel, L; Lee, P; Ordentlich, P; Sorensen, R; Younes, A, 2016) |
" Additionally, the dose-response curve test indicated that MS-275 has a U-shape effect on ethanol self-administration with the dose of 500 µM as the most efficient dose." | 1.42 | The Class I-Specific HDAC Inhibitor MS-275 Decreases Motivation to Consume Alcohol and Relapse in Heavy Drinking Rats. ( Alaux-Cantin, S; Jeanblanc, J; Jeanblanc, V; Lemoine, S; Naassila, M, 2015) |
Research
Studies (3)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Simon-O'Brien, E | 1 |
Alaux-Cantin, S | 2 |
Warnault, V | 1 |
Buttolo, R | 1 |
Naassila, M | 2 |
Vilpoux, C | 1 |
Jeanblanc, J | 1 |
Lemoine, S | 1 |
Jeanblanc, V | 1 |
Batlevi, CL | 1 |
Kasamon, Y | 1 |
Bociek, RG | 1 |
Lee, P | 1 |
Gore, L | 1 |
Copeland, A | 1 |
Sorensen, R | 1 |
Ordentlich, P | 1 |
Cruickshank, S | 1 |
Kunkel, L | 1 |
Buglio, D | 1 |
Hernandez-Ilizaliturri, F | 1 |
Younes, A | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma[NCT00866333] | Phase 2 | 49 participants (Actual) | Interventional | 2009-04-13 | Terminated (stopped due to Terminated prior to completion of accrual per corporate decision.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Duration of Objective Response for Participants Achieving CR or PR
Duration of objective response was defined as the number of days from the start date of CR or PR (whichever status is recorded first), until the first date that recurrent or progressive disease was objectively documented. (NCT00866333)
Timeframe: Regimen 1 and 2 median follow-up 36.6 months; Regimen 3 median follow-up 18.4 months
Intervention | months (Median) |
---|---|
Regimen 1: Entinostat 10 mg | NA |
Regimen 2: Entinostat 10 mg/15 mg | 28.6 |
Regimen 3: Entinostat 15 mg | 8.3 |
Percentage of Participants With Best Overall Response Based on the Participant's Best Response Documented Through the Entire Course of Protocol Therapy
Best Overall Response was defined as Complete Response (CR) or Partial Response (PR). Tumor response was assessed by the Investigators using the International Working Group revised response criteria for malignant lymphoma (Cheson, Pfistner et al. 2007). CR was defined as complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities definitely assignable to HL. PR was defined as: At least a 50% decrease in sum of the products of the greatest diameters (SPD) of the six largest dominant nodes or nodal masses, No increase in the size of other nodes, No new sites of disease. (NCT00866333)
Timeframe: Regimen 1 and 2 median follow-up 36.6 months; Regimen 3 median follow-up 18.4 months
Intervention | percentage of participants (Number) |
---|---|
Regimen 1: Entinostat 10 mg | 8.3 |
Regimen 2: Entinostat 10 mg/15 mg | 17.6 |
Regimen 3: Entinostat 15 mg | 16.7 |
Percentage of Participants With Best Overall Response Based on the Participant's Best Response That is Documented Within the First 6 Cycles of Protocol Therapy
Best Overall Response was defined as Complete Response (CR) or Partial Response (PR). Tumor response was assessed by the Investigators using the International Working Group revised response criteria for malignant lymphoma (Cheson, Pfistner et al. 2007). CR was defined as complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities definitely assignable to HL. PR was defined as: At least a 50% decrease in sum of the products of the greatest diameters (SPD) of the six largest dominant nodes or nodal masses, No increase in the size of other nodes, No new sites of disease. (NCT00866333)
Timeframe: Up to 6 months
Intervention | percentage of participants (Number) |
---|---|
Regimen 1: Entinostat 10 mg | 8.3 |
Regimen 2: Entinostat 10 mg/15 mg | 11.8 |
Regimen 3: Entinostat 15 mg | 16.7 |
Number of Participants With Serious Adverse Events (SAE) and Adverse Events (AEs)
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A Treatment-Emergent Adverse Event (TEAE) is an AE that occurred after receive study drug. Any changes from baseline in vital signs, electrocardiogram results, and laboratory parameters assessed by the investigator to be clinically significant were reported as AEs. A SAE is defined as an AE that: is fatal, is life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity is a congenital anomaly/birth defect, is another significant medical hazard, such as new malignancy. (NCT00866333)
Timeframe: First dose to within 30 days of the last dose of study drug (Up to 34 months)
Intervention | Participants (Count of Participants) | |
---|---|---|
Any TEAE | SAE | |
Regimen 1: Entinostat 10 mg | 16 | 2 |
Regimen 2: Entinostat 10 mg/15 mg | 17 | 7 |
Regimen 3: Entinostat 15 mg | 16 | 3 |
Trials
1 trial available for entinostat and Recrudescence
Article | Year |
---|---|
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Cytokines; Drug Resistanc | 2016 |
Other Studies
2 other studies available for entinostat and Recrudescence
Article | Year |
---|---|
The histone deacetylase inhibitor sodium butyrate decreases excessive ethanol intake in dependent animals.
Topics: Acetylation; Alcoholism; Analysis of Variance; Animals; Benzamides; Butyric Acid; Central Nervous Sy | 2015 |
The Class I-Specific HDAC Inhibitor MS-275 Decreases Motivation to Consume Alcohol and Relapse in Heavy Drinking Rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Benzamides; Disease Models, Animal; Dose-Re | 2015 |